Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Glenn Coleman is EVP & Chief Financial Officer at Charles River Laboratories. OQRO lists 3 transactions filed with the SEC under this name, the latest on Oct 3, 2026, each linked to the official Form 4.
EVP & Chief Financial Officer
Disclosures on record
3
Companies involved
1
Glenn Coleman bought shares on the open market in 2009 and 2023, and has not bought since 2023 across 3 companies. Sales in 11 of the 18 years since 2009.
Glenn Coleman reported 2 open-market purchases and 35 sales since 2009; purchases in 2 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $297K1×1 trade | — |
| 2022 | — | $414K1×1 trade |
| 2021 | — | $4.37M6×6 trades |
| 2020 | — | $925K5×5 trades |
| 2019 | — | $402K2×2 trades |
| 2018 | — | $1.05M3×3 trades |
| 2017 | — | $829K2×2 trades |
| 2016 | — | $252K1×1 trade |
| 2014 | — | $971K2×2 trades |
| 2013 | — | $146K6×6 trades |
| 2012 | — | $78K4×4 trades |
| 2011 | — | $52K3×3 trades |
| 2009 | $12K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Charles River LaboratoriesCRL
3 disclosures · May 2026 – Oct 2026
Sep 30, 202610disclosed Oct 3
DetailsOfficial recordMay 29, 20266,640disclosed Jun 2
DetailsOfficial recordMay 1, 202621Kdisclosed May 4
DetailsOfficial recordAs of the latest filing on , Glenn Coleman reported holding 27,762 shares of Charles River Laboratories (CRL), worth about $9.25M at the last close of $333 (Nov 18, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Charles River Laboratories CRL | 27,762 | 28K direct | $333 | $9.25M | Sep 30, 2026 |
Is this Glenn Coleman’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Sep 30, 2026, Glenn Coleman reported holding 27,762 shares of Charles River Laboratories (CRL). At the last close of $333 on Nov 18, 2026, that is about $9.25M. This is the stake disclosed in filings, not a net worth.
No public filing gives Glenn Coleman's net worth. What SEC Form 4 shows is the stock stake: 27,762 shares of Charles River Laboratories (CRL), about $9.25M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Glenn Coleman bought shares on the open market in 2009 and 2023, and has not bought since 2023 across 3 companies. Sales in 11 of the 18 years since 2009.
In SEC filings since 2009: the latest open-market purchase is from 2023; the latest open-market sale is from 2022.
3 companies: Dentsply Sirona (XRAY, 2023), Integra Lifesciences Holdings (IART, 2016–2022), Curtiss-Wright (CW, 2009–2014).
Glenn Coleman reported 0 open-market purchases and 20 sales here, 2016 to 2022.
Glenn Coleman reported 1 open-market purchase and 15 sales here, 2009 to 2014.
Glenn Coleman reported 1 open-market purchase and 0 sales here, 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.